Audit 369942

FY End
2024-12-31
Total Expended
$217.93M
Findings
3
Programs
119
Year: 2024 Accepted: 2025-09-30

Organization Exclusion Status:

Checking exclusion status...

Findings

ID Ref Severity Repeat Requirement
1157919 2024-001 Material Weakness Yes P
1157920 2024-001 Material Weakness Yes P
1157921 2024-001 Material Weakness Yes P

Programs

ALN Program Spent Major Findings
97.036 Covid-19 - Federal Emergency Management Agency Disaster Relief Fund $88.48M Yes 0
84.268 Federal Direct Student Loans - Hackensack Meridian School of Medicine $27.66M Yes 0
21.027 Covid-19 - Coronavirus State Fiscal Recovery Fund $26.04M Yes 0
93.855 Covid-19 - Metropolitan Antiviral Drug Accelerator $23.91M Yes 0
21.027 Covid-19 - Coronavirus State Fiscal Recovery Fund Project 2024 $10.44M Yes 0
84.268 Federal Direct Student Loans - Jfk Muhlenberg School $3.41M Yes 1
93.310 Enriching Echo Cohorts with High-Risk Pregnancies and Children with Disabilities (enriching Echo) $3.06M Yes 0
84.181 Services: Early Intervention System, Special Education Grants for Infants and Families $2.84M Yes 0
93.855 Center to Develop Therapeutic Countermeasures to High-Threat Bacterial Agents $2.79M Yes 0
93.378 Integrated Care for Kids Model $2.32M Yes 0
93.855 Harnessing B Cells for Tb Vaccine Development to Improve Therapy of Tb and Tb-Hiv Coinfection $1.12M Yes 0
84.063 Federal Pell Grant Program - Jfk Muhlenberg School $1.06M Yes 1
93.855 Optimization of Rifamycins to Overcome Intrinsic Resistance of Nontuberculous Mycobacteria to Improve Treatment of Ntm Lung Disease $1.02M Yes 0
93.493 Community Project Funding/congressionally Directed Spending ‐ Construction $777,702 Yes 0
93.396 Identifying and Characterizing Functional Noncoding Mutations in Multiple Myeloma $717,876 Yes 0
93.393 Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge $683,620 Yes 0
93.839 Dot1l, Reconstitution of Plasmacytoid Dendritic Cells and Alloimmunity $649,622 Yes 0
93.396 Id3 Regulation of Tissue-Infiltrating T Cells Mediating Graft-Versus-Host Disease and Leukemia Rejection $616,267 Yes 0
93.855 Tcf1 Programs Cd8 T Cell Responses to Enhance Viral and Cancer Immunity $609,369 Yes 0
93.917 Hiv Care Formula Grants - Ryan White Part B $609,132 Yes 0
93.855 Translational Approaches to Improve Understanding and Outcome in Tuberculous Meningitis $602,403 Yes 0
93.243 Icare Integrated Care for Addiction Recovery Expansion $590,817 Yes 0
93.855 Immunometabolic Regulations of Pulmonary Tb Pathogenesis by Adipose Tissue $587,073 Yes 0
93.855 Determinants of Tb Control, Relapse and Reinfection $581,494 Yes 0
93.396 Harnessing the Thymus for Long-Term Tumor Control with Hematopoietic Stem Cell-Derived Naïve Car T Cells $539,249 Yes 0
93.855 Transmission Aerobiology of M. Tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across An Evolutionary Bottleneck $470,789 Yes 0
93.855 Critical Factors Influencing Echinocandin Resistance in Candida Glabrata $460,594 Yes 0
93.855 Hx Nih Ctcf in Cd8 Tcell $459,836 Yes 0
12.420 Mechanisms of Impaired Swallowing, Speech, and Voice in Parkinson's Disease $390,082 Yes 0
93.396 Nuclear Envelope and Predisposition to Hepatic Neoplasia $387,071 Yes 0
16.045 Project Heal: Expansion of Community-Based Violence Intervention & Prevention Initiatives $380,774 Yes 0
16.575 Community-Based Violence Intervention Program $380,567 Yes 0
93.396 Study of the Il-33-Driven Immune Cell Organization Underpinning Responses to Immune Checkpoint Blockade Cancer Therapy $380,562 Yes 0
93.433 Nidilrr Disability and Rehab. Research Projects Tbi Model Systems $371,259 Yes 0
93.855 Discovery of Novel Lead-Target Pairs and Identification of All-Oral Bactericidal Drug Regimens for Mycobacterium Abscessus Lung Disease $353,480 Yes 0
93.855 Antibacterial Resistance Leadership Group (arlg) $327,571 Yes 0
93.865 Epigenetics of Down Syndrome $304,473 Yes 0
93.855 Novel Bi-Specific Immunotherapeutic Against High-Threat Gram-Negative Pathogens $302,666 Yes 0
93.110 Pediatric Mental Health Care Access Program 2024 $301,058 Yes 0
93.855 Lesion Pharmacokinetics and Pharmacodynamics to Design New Drugs and Drug Combinations for Tuberculosis $299,454 Yes 0
93.273 Peptide Therapy for Alcohol-Induced Cns Injury $265,919 Yes 0
93.855 A Dual-Beta-Lactam Strategy for Treating Multidrug Resistant M Abscessus $252,357 Yes 0
93.855 Preclinical Design and Clinical Translation of Tb Regimens (predistr) Consortium $249,603 Yes 0
93.398 Leveraging Behavioral Science to Improve Patient Understanding of Advanced Cancer $241,714 Yes 0
93.398 Elucidating the Role of Smad4 in Colorectal Cancer $235,765 Yes 0
93.853 Neutrophil Extracellular Traps and Associated Pathogenesis in Tbi: A Novel Peptide Therapeutic Strategy $225,448 Yes 0
93.855 Elucidating Mediators of Genetic Instability in Candida Glabrata $222,589 Yes 0
93.855 Identifying Drug-Resistant Candida Species Using Superselective Primer Pcr $219,703 Yes 0
93.855 Celiac and Inflammatory Bowel Disease: Functional Post-Gwas Approach $217,443 Yes 0
12.420 Therapeutic Implications of Tnbc-Specific Etv6 Rearrangements: Chemoresistance and Immune Evasion $210,371 Yes 0
93.398 Experimental Evolution of Pancreatic Cancer $206,970 Yes 0
93.247 Ane- Nurse Practitioner Residency Program $201,375 Yes 0
93.395 Study of Interleukin 33 As A New Immunotherapy of Lung Cancer $195,983 Yes 0
93.397 Georgetown Lccc Ccsg $192,327 Yes 0
93.914 Ryan White Services for People Living with Hiv $185,783 Yes 0
93.924 Ryan White Hiv/aids Dental Reimbursements $177,751 Yes 0
93.397 Epigenetic Therapies - New Approaches, Project 1 $167,429 Yes 0
11.617 Dna Research Sequence Project $167,339 Yes 0
93.855 Novel Strategies for Antibiotic Combinations to Combat Gram-Negative Superbugs $165,630 Yes 0
93.590 Community Prevention Direct Service $164,829 Yes 0
93.870 New Jersey Home Visiting Initiative: Parents As Teachers $152,676 Yes 0
93.393 Using A Mixed Methods Approach to Understand Shared Decision-Making in Lung Cancer Screening $144,520 Yes 0
93.121 Dissecting Cell Composition and Drug Sensitivity in Humanadenoid Cystic Carcinomas (accs) $140,352 Yes 0
93.914 Ryan White $136,025 Yes 0
93.395 Targeting Transcriptional CO-Repressor Corest Complex in Melanoma $125,276 Yes 0
93.838 Clock (collaborative Long-Term Study of Outcomes of Covid-19 in Kids) Consortium for Pasc Phase II Recover Pediatric Cohort $124,264 Yes 0
93.243 Substance Abuse and Mental Health Services - Projects of Regional and National Significance $122,061 Yes 0
12.420 Biomarkers and Pathogenesis of Cutaneous Fibrosis $121,666 Yes 0
93.394 Molecular Markers of Risk of Subsequent Invasive Breast Cancer in Women $119,182 Yes 0
10.331 Hackensack Meridian Health Fresh Match Initiative (hmhfm) $117,572 Yes 0
93.853 Comparing Treatment Approaches to Promote Inpatient Rehabilitation Effectiveness for Traumatic Brain Injury (care 4 Tbi) $117,255 Yes 0
93.855 A Preclinical Program for Targeting Mycobacterium Tuberculosis Kasa $112,605 Yes 0
93.393 Tmem, Menacalc, and Menainv As Prognostic and Predictive Markers for Breast Cancer Metastasis $112,126 Yes 0
93.243 Hmh Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (aide) $107,308 Yes 0
93.393 Population-Based Assessment of Patient-Reported Outcomes in Adults Living with Metastatic Colorectal Cancer $98,550 Yes 0
12.420 Role of Core-Binding Factor Rearrangements in Triple-Negative Breast Cancer Progression and Immune Evasion $97,528 Yes 0
93.393 Dissemination of A Breast Reconstruction Decision Tool Through Social Media and Online Communities $95,108 Yes 0
93.110 Pediatric Mental Health Care Access Program 2025 $93,499 Yes 0
93.855 Within-Host Diversity of Gram Negative Bacteria From Bloodstream Infections $89,058 Yes 0
93.398 Optimizing Adherence to Lung Cancer Screening: Applying Theory and Implementation Science to Participant Engagement $88,688 Yes 0
93.991 Childhood and Adult Asthma Program 2024 $87,238 Yes 0
97.025 Nj-Tf1 Deployment Tropical Cyclone Helene $84,903 Yes 0
93.398 Cancer Misinformation and Use of Complementary and Alternative Therapy (cam) Among Patients with Cancer $84,184 Yes 0
84.007 Federal Supplemental Education Opportunity Grant Program - Jfk Muhlenberg School $80,000 Yes 1
93.855 C5a/c5ar1 Signaling in Protective Immunity During Invasive Candidiasis $78,616 Yes 0
93.855 Modulating Costimulation Pathways to Improve Follicular Helper T Cell and Antibody Responses $69,520 Yes 0
93.940 Integrated Hiv Programs $67,000 Yes 0
93.855 Serine/threonine Kinase Signaling in Beta-Lactam Resistance of Staphylococcus Aureus $63,902 Yes 0
93.395 Mosaic: Rct of A Digital Health Intervention Delivering Peer Support Narratives and Psychoeducation to English and Spanish-Speaking Stem Cell Transplant Recipients $56,983 Yes 0
93.855 Combatting Natural Resistance and Persistence in Non-Tb Mycobacterial Disease $56,683 Yes 0
93.395 Lncrna Epic1 Induces Immunotherapy Resistance by Activating Ezh2 in Breast Cancer $47,437 Yes 0
93.433 The Traumatic Brain Injury Model Systems National Data and Statistical Center $38,700 Yes 0
93.393 Bridging Information Divides and Gaps to Ensure Survivorship $37,960 Yes 0
93.917 Ryan White Title B $33,288 Yes 0
93.855 Ezh2 Regulates Follicular Helper T Cell Differentiation $32,908 Yes 0
93.846 Stopping Hydrochloroquine in Elderly Lupus Disease (shield) $32,790 Yes 0
93.855 Synthesizability-Constrained Expansion and Multi-Objective Evolution of Antitubercular Compounds $31,469 Yes 0
12.420 Engaging Retiring Military Personnel in Va Lung Cancer Screening Through Codesigned Communication Campaign $30,858 Yes 0
93.393 Multilevel Interventions to Increase Adherence to Lung Cancer Screening $26,707 Yes 0
93.994 Special Child Health Child Evaluation Centers 2024 $25,567 Yes 0
93.855 Antibiotic Resistance Among Hypermutator Carbapenem Resistant Klebsiella Pneumoniae $25,366 Yes 0
93.153 Ryan White Part D $23,414 Yes 0
93.994 Special Child Health Child Evaluation Centers 2025 $23,405 Yes 0
93.397 Epigenetic Therapies - New Approaches, Pathology Core $20,977 Yes 0
93.855 Novel Dual-Stage Antimalarials: MacHine Learning Prediction, Validation and Evolution $20,886 Yes 0
93.243 Expanded Interprofessional Medication-Assisted Treatment Training Program $19,943 Yes 0
93.397 Georgetown University Lombardi Cancer Center Support Grant - Improve Efficacy of Car-T Cells in Treatment of Pdac $18,243 Yes 0
93.855 Defining Stim1 Function at the Immunological Synapse $16,196 Yes 0
93.866 Escitalopram in Agitation in Alzheimer Disease $15,728 Yes 0
93.393 Bridging Information Divides and Gaps to Ensure Survivorship; the Bridges Randomized Controlled Trial of Multilevel Intervention to Improve Adherence to Childhood Cancer Survivorship $15,000 Yes 0
93.397 Fit & Quit 2.0: Feasibility and Usability Testing $14,077 Yes 0
93.393 Empathic Communication Skills Training to Reduce Lung Cancer Stigma $13,305 Yes 0
93.837 Role of Lsd1 in Triple Negative Breast Cancer Development and Therapeutic Response $11,898 Yes 0
93.226 Simulation to Improve Infection Prevention and Patient Safety: the Sipps Trial $10,016 Yes 0
93.866 Use of the Kf Modified Story Memory Technique to Improve New Learning and Memory in Individuals with Mild Cognitive Impairment $6,500 Yes 0
93.865 The Patient Journey for Children with Medical Complexity During the Pandemic Era and Its Implications $5,860 Yes 0
93.394 Uncover: Underlying Novel Causes of Onset of Very Early Cancer Research $3,983 Yes 0
93.855 Bacterial Characteristics of Community-Associated Carbepenem-Resistant Enterobacteriaceae $3,047 Yes 0
12.420 Host-Directed Approaches to Target Granuloma Pathways for Treatment Shortening in Tuberculosis $1,263 Yes 0

Contacts

Name Title Type
LV8GL8MLU9A3 Nora Moustafa Auditee
8483033363 Timothy Weld Auditor
No contacts on file

Notes to SEFA

The accompanying Schedule of Expenditures of Federal Awards (the “Schedule”) presents the activities of the federal financial assistance programs of the Network that have been financed by the U.S. Government. The information in this Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (“Uniform Guidance”). Therefore, some amounts presented in this Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller, OASC-3, A Guide for Hospitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Schedule is presented on the accrual basis of accounting. Because the Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. While certain awards on the Schedule have program names identified as award year 2025, only expenses incurred during the year ended December 31, 2024 are reported on the Schedule. These awards have grant periods that do not align with the Network’s calendar year end.
Full Assistance Listing Numbers (“ALN”) and pass through award numbers are presented where available and applicable.
The Network is responsible only for the performance of certain administrative duties with respect to the Federal Direct Student Loan Program and, accordingly, the total outstanding loans are not included in the Network’s consolidated financial statements. The Network operates two distinct Schools, the HMSOM and the JFKSON, that participate in the Federal Direct Student Loan Program. Each School possesses its own Employer Identification Number and independently manages its student financial aid regulatory compliance. It is not practical to determine the balance of loans outstanding to students under this program for either School as of December 31, 2024. The Schedule includes loans granted in 2024.
As of December 31, 2024, the Network recorded $88,476 claims to FEMA under ALN 97.036. The claims submitted represented incurred eligible operating expenses attributed to the Network’s response to COVID-19 which were not only expended but also obligated by the federal and state agencies. All expected FEMA claims related to COVID-19 operating expenses incurred were obligated as of December 31, 2024.

Finding Details

Management’s Views and Corrective Action Plan is included at the end of this re